Ambrx Biopharma Inc.·4

May 5, 4:10 PM ET

Aromando Andrew 4

4 · Ambrx Biopharma Inc. · Filed May 5, 2023

Insider Transaction Report

Form 4
Period: 2023-04-28
Aromando Andrew
Chief Operating Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-04-28+2,600,0002,600,000 total
    Exercise: $1.38Exp: 2033-04-28Ordinary Shares (2,600,000 underlying)
Footnotes (4)
  • [F1]The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
  • [F2]Grant awarded as an inducement grant in connection with the Reporting Person's appointment as Chief Operating Officer of the Issuer.
  • [F3]Twenty-five percent of the Ordinary Shares subject to the option vested on April 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date.
  • [F4]The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION